Our overachieving goal is to identify the biological mechanisms that contribute to the persistence of HIV despite prolonged antiretroviral therapy (ART), and to therapeutically target these mechanisms to eliminate persistently infected cells and restore local immune responses—with the ultimate objective of controlling viral rebound upon ART interruption.

​

With continuous funding from CIHR over the past decade, the Canadian HIV Cure Enterprise (CanCURE) has developed unique expertise in the study of tissue reservoirs. This sustained investment has transformed HIV cure research in Canada into a collaborative, interdisciplinary model for knowledge generation and translation.

​

Moreover, through meaningful engagement with communities of people with HIV (PWH), and a commitment to addressing their medical needs, CanCURE has paved the way for novel, targeted therapeutic strategies. These interventions are currently being evaluated in animal models and have progressed to pilot clinical trials.